38 results
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer
8-K
EX-99.1
sl837my08 v0b
11 Mar 24
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
7:02am
8-K
EX-99.1
4bskp88s4 3h2317w1
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
EX-99.2
gldgovs
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
t5dr 6ob6xz3t
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
dk30vv8
11 Dec 23
Other Events
12:03pm
8-K
EX-99.1
czxeg9q5
1 Nov 23
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
4:02pm
8-K
EX-99.1
xrennevkz9 8ui
13 Jul 23
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:18pm
8-K
EX-99.1
wq3svngbb8jzptsw
13 Apr 23
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:02pm
8-K
EX-99.2
zmf34hvgrc5c
12 Dec 22
Other Events
5:36pm
8-K
EX-99.1
3l9pqt
14 Sep 22
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
4:01pm